ONC Stock Overview
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer.
+ 2 more risks
Oncolytics Biotech Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$1.72|
|52 Week High||CA$2.96|
|52 Week Low||CA$1.06|
|1 Month Change||35.43%|
|3 Month Change||16.22%|
|1 Year Change||-33.33%|
|3 Year Change||102.35%|
|5 Year Change||-64.50%|
|Change since IPO||-87.93%|
Recent News & Updates
Here's Why We're Watching Oncolytics Biotech's (TSE:ONC) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
|ONC||CA Biotechs||CA Market|
Return vs Industry: ONC underperformed the Canadian Biotechs industry which returned 11.1% over the past year.
Return vs Market: ONC underperformed the Canadian Market which returned 0.7% over the past year.
|ONC Average Weekly Movement||8.7%|
|Biotechs Industry Average Movement||13.0%|
|Market Average Movement||10.6%|
|10% most volatile stocks in CA Market||18.9%|
|10% least volatile stocks in CA Market||4.3%|
Stable Share Price: ONC is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ONC's weekly volatility (9%) has been stable over the past year.
About the Company
Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone receptor-positive/human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC.
Oncolytics Biotech Inc. Fundamentals Summary
|ONC fundamental statistics|
Is ONC overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ONC income statement (TTM)|
|Cost of Revenue||CA$949.77k|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.42|
|Net Profit Margin||0.00%|
How did ONC perform over the long term?See historical performance and comparison